Mariangela Garofalo
 | Department of Pharmaceutical and Pharmacological Sciences, University of Padova e-mail: mariangela.garofalo@unipd.it ORCID ID 0000-0002-5001-7826 |
Short cv
Mariangela Garofalo has recently joined the Department of Pharmaceutical and Pharmacological Sciences at the University of Padova as Researcher. She received a Master Degree in Medical Biotechnology in 2011 at the University Federico II of Naples and a PhD in Biochemistry and Cell and Molecular Biology, in co-supervision University of Naples - University of Helsinki in 2015. During her PhD she moved to Finland where she spent 2 years as visiting student finalizing her PhD thesis in the ImmunoVirotherapy Lab at the Division of Pharmaceutical Biosciences, University of Helsinki (2013-2015). From 2015 to 2017 she carried out her post-doctoral research at the Faculty of Pharmacy (University of Helsinki); after that she worked as post-doctoral researcher at the Department of Oncology and Hemato-Oncology at the University of Milan (2017-2019) where she was involved in multidisciplinary research activities in collaboration with IRCCS Istituto Nazionale dei Tumori (INT).
Teaching
Office hours
To be agreed by email
Availability for Thesis Projects
Thesis projects are available within the research area of cancer drug delivery. For further information please set up an appointment by email
Scientific Activities
Oncolytic virotherapy is emerging as a potential approach to treat cancer by using viruses, which are specifically engineered to preferentially infect, replicate in and kill cancer cells instead of normal cells. Currently, this therapy requires the intratumoral administration of the viruses, which is restricting its application to injectable lesions. Ideally, the possibility to systemically deliver tumor-tropic oncolytic viruses would provide a chance of reaching even small metastases localized throughout the body. However, systemic administration is limited by the presence of neutralizing antibodies resulting in a decreased efficacy. Therefore, my research interests aim to overcome this limitation by using extracellular vesicles for the systemic delivery of therapeutic oncolytic viruses and drugs. The final aim is to design and evaluate antineoplastic properties of extracellular vesicles loaded with therapeutic agents in order enhance their clinical efficacy in vitro and in vivo. The projects deal with the definition of tools and techniques to develop drug delivery systems using extracellular vesicles and oncolytic viruses, their biopharmaceutical characterisation and in vivo preclinical studies.
So far, my research has been on:
- Oncolytic viruses as novel carriers in combination with peptides and chemotherapeutic drugs
- Extracellular vesicles loaded with therapeutic agents and fluorescent markers. This strategy allows to insulate the delivered agents, thus potentially preventing undesired off target effects associated with their systemic delivery.
Technical expertise
- Molecular Biology: DNA/RNA isolation, purification, PCR, ELISA, IFN-gamma ELISPOT, Immunocytochemistry staining (ICC)
- Cellular analysis: tissue culture techniques
- Basic virology: adenovirus cloning, virus production and purification, PCR, ICC, TCID50, VP
- Animal studies: immunodecificent, immunocompetent and humanized mice (work experience in a cleanroom and BSL-3 class lab)
- Animal imaging systems: CCD-camera
- Other tecniques: size and zeta-potential measurements, H&E staining
Publications
Heterologous and cross-species tropism of cancer derived extracellular vesicles. Garofalo M ,Villa A, Crescenti D, Marzagalli M, Kuryk L, Limonta P, Mazzaferro V, Ciana P. Theranostics 2019. Doi:10.7150/thno.34824 (in press)
Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus in immunocompetent mice. Garofalo M, Villa A, Rizzi N, Kuryk L, Rinner B, CerulloV, YliperttulaM, MazzaferroV, CianaP. Journal of Controlled Release 2019,294:165-175
Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies. Garofalo M, Villa A, Rizzi N, Kuryk L, Mazzaferro V, Ciana P. Viruses 2018, 10(10), 558
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. Garofalo M, Saari H, Somersalo P, Crescenti D, Kuryk L, Aksela L, Capasso C, Jalasvuori M, Cerullo V, Ciana P, Yliperttula M. Journal of Controlled Release 2018, 283:223-234.
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Kuryk L, Haavisto E, Garofalo M, Capasso C, Hirvinen M, Pesonen S, Ranki T, Vassilev L, Cerullo V. International Journal of Cancer 2016, 139(8):1883-93
Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the anti-tumor activity. Garofalo M,, Iovine B, Kuryk L, Capasso C, Hirvinen M, Vitale A, Yliperttula M, Bevilacqua MA, Cerullo. V. Molecular Cancer Therapeutics 2016, 15(4):651-60
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V. Oncoimmunology 2015,5(4):e1105429
Research projects and Funds
Research projects and Funds
